Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ARDS - Biotech Pops On New Patient Enrollment Announcement

ARDS - Biotech Pops On New Patient Enrollment Announcement

Aridis Pharmaceuticals Inc.

A California-based %Biotech company turned heads on Wednesday after the company announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase 2a clinical trial of AR-501 in %CysticFibrosis (CF) patients. According to the release, the company is on track to complete database lock, data analyses, and disclose top-line data in the first quarter of 2023.

This sent shares of %AridisPharmaceuticals () up to $0.9833/share (+9.26%) at the early session high. Keep you eyes on this one for sessions to come!

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.

Stock Information
Company Name: Aridis Pharmaceuticals Inc.
Stock Symbol: ARDS
Market: NASDAQ
Website: aridispharma.com
Menu
ARDS ARDS Quote ARDS Short ARDS News ARDS Articles ARDS Message Board
Get ARDS Alerts

News, Short Squeeze, Breakout and More Instantly...